Anuh Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case

Anuh Pharma (NSE: ANUHPHR) is a Pharmaceutical Formulations and APIs company trading at Rs 77.77 with a market capitalisation of Rs 389 crore. Analysts have set the Anuh Pharma share price target at Rs 93.3 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Anuh Pharma including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Anuh Pharma Share Price Target 2026: Key Takeaways

• Anuh Pharma share price target 2026: Rs 93.3 (20% upside from CMP Rs 77.77)
• Bull case: Rs 115 | Bear case: Rs 62.2
• Ticker: ANUHPHR | Sector: Pharmaceutical Formulations and APIs | MCap: Rs 389 crore
• 52W range: Rs 55 to Rs 139 | PE: 15x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Anuh Pharma Company Overview

Anuh Pharma (NSE: ANUHPHR) is a Mumbai-based pharmaceutical company manufacturing sulpha drugs, antibiotic formulations, and pharmaceutical intermediates for domestic hospital distribution and export. At CMP Rs 77.77 against a 52 week range of Rs 55 to Rs 139, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 389 crore with trailing PE of 15x. Compared to peers in pharma like Kilitch Drugs and Bal Pharma, Anuh Pharma is positioned as a potential re-rating candidate toward the Rs 93.3 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	ANUHPHR
Sector	Pharmaceutical Formulations and APIs
CMP (2026)	Rs 77.77
52 Week High	Rs 139
52 Week Low	Rs 55
Market Cap	Rs 389 crore
Trailing PE	15x
12-Month Analyst Target	Rs 93.3
Bull Case Target	Rs 115
Bear Case Target	Rs 62.2

Why Is the Anuh Pharma Share Price Target Set at Rs 93.3 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Anuh Pharma share price target of Rs 93.3 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating from CMP Rs 77.77. Until FY27 PAT delivery is confirmed, the Rs 93.3 objective represents a base case with execution risk attached.

Structural Sector Tailwinds in Pharmaceutical Formulations and APIs

The Pharmaceutical Formulations and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Anuh Pharma’s market position among peers in pharma like Kilitch Drugs and Bal Pharma creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 115 bull case to materialise, making sector monitoring essential for investors tracking the stock.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Anuh Pharma, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 93.3 analyst consensus in 2026.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Anuh Pharma’s Pharmaceutical Formulations and APIs operations. Policy support increases the probability of Anuh Pharma achieving its FY27 earnings targets, supporting the Rs 93.3 price objective.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Anuh Pharma is positioned as a beneficiary of institutional reallocation into the Pharmaceutical Formulations and APIs sector, providing a tailwind toward the Rs 115 bull case.

Anuh Pharma Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Anuh Pharma Share Price Target

Near-term support for Anuh Pharma is anchored close to the 52 week low of Rs 55. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a reference while awaiting the FY27 earnings confirmation that would support the full Rs 93.3 objective.

12-Month Anuh Pharma Share Price Target 2026

The 12-month Anuh Pharma share price target 2026 is Rs 93.3, implying approximately 20 percent upside from CMP Rs 77.77. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows into the Pharmaceutical Formulations and APIs sector. Track live price on NSE under ticker ANUHPHR.

Long Term Anuh Pharma Share Price Target: FY27 to FY28

The long term Anuh Pharma share price target for FY27 to FY28 is Rs 115 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in pharma like Kilitch Drugs and Bal Pharma, and sustained institutional buying are the three conditions needed to reach Rs 115 over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Anuh Pharma in 2026

Bull Case Anuh Pharma Share Price Target: Rs 115

The bull case Anuh Pharma share price target of Rs 115 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. Under this scenario, Anuh Pharma re-rates toward higher peer multiples, making Rs 115 achievable within FY28, representing approximately 45 percent upside from the current CMP of Rs 77.77.

Bear Case Anuh Pharma Share Price Target: Rs 62.2

The bear case Anuh Pharma share price target of Rs 62.2 materialises if FY27 earnings disappoint or FII outflows depress the broader market. Under this scenario, the stock risks testing 52 week low support near Rs 55, and investors should reassess the thesis before deploying additional capital.

Scenario	Target	Key Conditions
Bull Case	Rs 115	FY27 earnings beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 93.3	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 62.2	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Anuh Pharma 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions triggered by the US reciprocal tariff announcement in 2026 have reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains a prominent macro risk to the Anuh Pharma share price target of Rs 93.3 and could push the stock toward the bear case of Rs 62.2.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress multiples. This is the most direct company-specific risk to the Rs 93.3 analyst price objective. Investors should monitor quarterly results and management commentary, especially signals about demand environment, pricing power, and margin compression in Pharmaceutical Formulations and APIs.

Competitive Intensity Among Pharmaceutical Formulations and APIs Peers

Intensifying competition from peers in pharma like Kilitch Drugs and Bal Pharma could compress Anuh Pharma’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory is that underpins the Rs 93.3 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns. Investors should size positions carefully and maintain stop losses to protect capital if broader market de-rating continues.

How to Invest in Anuh Pharma

Check the Univest Screener for live data

Before considering any investment based on the Anuh Pharma share price target of Rs 93.3, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Pharmaceutical Formulations and APIs sector demand and competition.

Open a Demat and trading account with a SEBI registered stockbroker to trade Anuh Pharma (NSE: ANUHPHR) with regulatory protection. Before executing any order, study the competitive landscape among peers in pharma like Kilitch Drugs and Bal Pharma to assess whether Anuh Pharma’s competitive position justifies the Rs 93.3 valuation.

Plan your entry using the 52 week low of Rs 55 as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.

Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio, especially in the Pharmaceutical Formulations and APIs space where sectoral cycles can amplify volatility beyond initial expectations.

Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Anuh Pharma’s live share price and receive daily stock recommendations from SEBI registered analysts.

FAQs on Anuh Pharma Share Price Target 2026

What is the Anuh Pharma share price target for 2026?

Ans. The Anuh Pharma share price target 2026 is Rs 93.3, implying approximately 20 percent upside from CMP Rs 77.77. The bull case target is Rs 115 and the bear case is Rs 62.2.

What was the Anuh Pharma share price target for 2025?

Ans. The 2025 price objective for Anuh Pharma was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 93.3, reflecting FY27 growth potential from the current CMP of Rs 77.77.

Is Anuh Pharma a good investment at Rs 77.77?

Ans. At Rs 77.77, Anuh Pharma offers potential upside toward Rs 93.3 if FY27 earnings recover as projected. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Anuh Pharma share price target 2026?

Ans. Key risks to the Anuh Pharma share price target of Rs 93.3 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results and management guidance is essential.

What is the 52 week high and low of Anuh Pharma?

Ans. The 52 week high of Anuh Pharma is Rs 139 and the 52 week low is Rs 55. At CMP Rs 77.77, the stock is trading below its 52 week high and offers upside toward the Rs 93.3 analyst price objective.

What are the main growth catalysts for Anuh Pharma in 2026?

Ans. Primary growth catalysts for Anuh Pharma in 2026 include FY27 PAT recovery, Pharmaceutical Formulations and APIs sector tailwinds, RBI rate cuts reducing cost of capital, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Anuh Pharma compare to its peers?

Ans. Anuh Pharma operates in Pharmaceutical Formulations and APIs alongside peers in pharma like Kilitch Drugs and Bal Pharma. At CMP Rs 77.77 with MCap Rs 389 crore, the company is positioned as a potential re-rating candidate toward the Anuh Pharma share price target of Rs 93.3 on FY27 earnings delivery.

What is the Anuh Pharma share price target for 2027?

Ans. The long-term Anuh Pharma share price target for FY27 to FY28 is Rs 115 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows into Indian equities. Consult a SEBI registered financial advisor for personalised guidance.